A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

Part of paid clinical trials in Miami, Florida.

Sponsor
Bristol-Myers Squibb
Study ID
NCT04949269
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Deucravacitinib — DRUG
    Specified dose on specified days
  • Famotidine — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to assess the drug levels of deucravacitinib after oral administration in healthy participants.

Key Dates

Start date
Jul 20, 2021
Status verified
Feb 2022
Primary completion
Jan 3, 2022
Completion
Jan 3, 2022

Study Design

Enrollment
61 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Part A
  • Experimental: Part B
  • Experimental: Part C
  • Experimental: Part D

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) of deucravacitinib [ Time Frame: Up to 7 days ]

Locations (2)

FacilityCityStateZIPSite coordinators
Quotient Sciences MiamiMiamiFlorida33126-
PPD Development, LPAustinTexas78744-

Find similar trials in Miami, FL

By research site
Quotient Sciences Miami· Miami, FLPPD Development, LP· Austin, TX

Related Studies